Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 3/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.53 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496376 | 0.95 | CNR1 (0.51) | GCGRCTNNB1TCF7L2CNR1SMN1; SMN2 | |
| SCHEMBL6489227 | 0.94 | CTNNB1 (0.48) | GCGRCTNNB1TCF7L2CNR1SMN1; SMN2 | |
| SCHEMBL6497806 | 0.93 | CNR1 (0.57) | GCGRCTNNB1TCF7L2CNR1SMN1; SMN2 | |
| SCHEMBL6499473 | 0.93 | CTNNB1 (0.53) | GCGRCTNNB1TCF7L2CNR1SMN1; SMN2 | |
| SCHEMBL6498069 | 0.92 | HDAC7 (0.49) | GCGRCTNNB1TCF7L2SMN1; SMN2HPGD | |
| SCHEMBL6488546 | 0.91 | CTNNB1 (0.54) | GCGRCTNNB1TCF7L2SMN1; SMN2HPGD | |
| SCHEMBL6489345 | 0.90 | GCGR (0.51) | GCGRCTNNB1TCF7L2CNR1SMN1; SMN2 | |
| SCHEMBL6489543 | 0.90 | CNR1 (0.53) | GCGRCTNNB1TCF7L2CNR1SMN1; SMN2 | |
| SCHEMBL6488828 | 0.90 | CNR1 (0.51) | GCGRCTNNB1TCF7L2CNR1SMN1; SMN2 | |
| SCHEMBL6489454 | 0.89 | MAOA (0.46) | GCGRCTNNB1TCF7L2SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | GCGR 1784/4885CTNNB1 1793/4885TCF7L2 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.